Inhibrx Biosciences, Inc. (INBX)

Inhibrx Biosciences, Inc. is trading at $122.80, down 3.08% on the session. The 50 day average sits at $94.86 and the 200 day at $88.02, which puts the stock in a uptrend. RSI is at 75.5, which reads as overbought, and MACD is bullish crossover. Volume is above average.

The nearest support is around $94.20 with resistance near $131.01, so that band frames the current range. Average daily movement is roughly $7.64, or about 6.2% of the share price, which is what any stop placement has to allow for. The overall health score of 70 out of 100 combines a trend score of 100, momentum of 78 and a risk score of 12.

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.